India’s Bilcare has expanded its clinical trial materials business in its own market with the opening of new packaging and storage capacity at its facilities in Pune, India.
Life sciences firm DSM has landed the contract to manufacture supplies of NicOx’ much vaunted anti-inflammatory agent naproxcinod and looks good for the long term deal.
Liverpool, UK-based biologics specialist Eden Biodesign has won three new manufacturing contracts - worth a total of £3m (€3.5m) – from clients in Europe and Asia.
Canadian contract manufacturer PharmEng International has managed to trim down its costs once again, but is still feeling the pain associated with the opening of its new facility in Sydney, Nova Scotia, and posted a loss of over C$8m (€5m).
Postponement of this year’s CPhI and P-MEC India events for “security reasons” may be only the first impact of last week’s Mumbai terror attacks on the country’s outsourcing industry, according to PwC’s life sciences head Sujay Shetty.
Althea Technologies has signed a contract manufacturing deal, under which it will produce Bio-Path’s lead novel therapeutic drug for upcoming clinical trials.
Janssen-Cilag’s quality control unit has found a defect in certain batches of its Ionsys (fentanyl hydrochloride) management system that could lead to a potentially life-threatening overdose.
Metrics’ new potent and cytotoxic drug development facility was the subject of a press conference at this year’s AAPS, where the company explained how the plant “raised the industry bar”.
Isogen will start operations in January at a new contract facility in Delaware that will provide small-scale sterile filling services to the pharmaceutical industry.
The US Food and Drug Administration (FDA) has issued draft guidance on process validation, updating its 1987 document to incorporate advances in manufacturing technology and thinking.
Patheon has signed a slew of agreements to boost its portfolio of contract drug development and manufacturing services, forging new alliances with Omnicare, Depomed, Senopsys and Solvias.
Canada’s Orbus Pharma has decided to exit the contract manufacturing business, saying that the division “posed a distraction to the core business and generated low or negative margins.”
CiVentiChem president Bhaskar Venepalli says that the CiVentiAnalytical unit, the firm’s new state of the art GLP/cGMP accredited laboratory in Cary, North Carolina, will help customers find novel method development solutions for API production.
Contract research group Recipharm has leased AstraZeneca Biotech Laboratory (ABL) in Sodertalje, Sweden, bolting on recombinant protein and monoclonal antibody development capabilities to its offering.
US company Irvine Pharmaceutical Services is gearing up to launch a new subsidiary company to provide fill-and-finish services for biopharmaceutical companies.
Patheon’s European HQ is up and running to help manage the firm’s growing European operations, specifically its development and commercial service offerings provided by units in France, Italy and the UK.
US Marshals have entered Celsus Laboratories to seize 11 lots of heparin, which contain contaminated material from China according to the US Food and Drug Administration (FDA).
Cambrex joined a number of its peers in the contract services sector by reporting pressure on third quarter sales and earnings, providing further evidence that outsourcing companies are not immune to the economic downturn.
The Indian government is planning on establishing pharmaceutical zones at major international airports to facilitate exports, according to local media reports.
Barrack Obama’s election as US president has been roundly welcomed by India’s generics sector, despite his somewhat contradictory desire to reduce the level of outsourcing but not "shy away" from globalisation.
The new MabDirect MM Fixed D column, launched by Denmark’s Upfront Chromatography, could be a boon for CMO’s and pilot plants working in the expanding bio-processing sector.
Caraco Pharmaceutical Laboratories, in which India’s Sun Pharmaceuticals holds a 76 per cent stake, has joined the list of generics manufacturers issued with an FDA warning on quality control issues.
Disposable bioreactor specialist Wave Biotech AG of Switzerland has been snapped up by its commercial and development partner Sartorius-Stedim for an undisclosed sum.
The US Food and Drug Administration (FDA) has issued a warning letter to Pharmalucence for alleged deviations from current good manufacturing practices (cGMP).
Jubilant Organosys, India's largest custom research and manufacturing services (CRAMS) provider, has reorganised its business in North America in the wake of its recent acquisitions of HollisterStier Laboratories and Draxis Specialty Pharmaceuticals.
Irish drugmaker Elan has shelved plans to sell its contracting arm EDT in favour of improving the division’s profitability, despite receiving what it describes as “considerable interest” in the unit.
The pharmaceutical industry must adapt its processes and strategies to cope with a new, tougher operating environment, according to Stefan Borgas, CEO of Lonza.
Ethex has withdrawn three lots of its generic drug dextroamphetamine sulphate, which is used to treat ADHD and narcolepsy, after analysis revealed that some oversized tablets had been produced.
Welcome to in-pharma technologist’s podcast. In the next three minutes Gareth Macdonald will take you through the top industry headlines this week. Product authenticity dominated the news, with US regulators announcing increased penalties for those convicted...
Sartorius Stedim Biotech (SSB) and Bayer Technology Services (BTS) have signed an exclusive cooperation agreement for the manufacture and marketing of UVivatec products.
The pharmaceutical industry sometimes seems besieged from all sides at present, and that has implications for contract manufacturers, according to Stefan Borgas, CEO of Lonza, at a recent meeting of the European Fine Chemicals Group (EFCG) in Frankfurt.
The MicroSEQ detection platform, developed by Applied Biosystems, looks set to revolutionise the detection of bacterial Mycoplasma in industrial scale biopharmaceutical manufacturing.
US company Ferro has said it will sell off its fine chemicals division to private equity firm Arsenal Capital Partners, which will rename the business as Novolyte Technologies, for $66m.
With big pharma and biopharma looking to cut costs and increase efficiency, liquid handling experts Artel have found that their services are in greater need than ever before.
Dutch sample and assay technology expert Qiagen has continued its march into the detection system market with the acquisition of Biotage’s Biosystems business.
The 2008 Nobel Prize for Chemistry has been awarded equally to three chemists "for the discovery and development of the green fluorescent protein (GFP),” one of the most important tools in bioscience.
After months of deliberations, a court in Iowa has opted to fine contract manufacturing company Cambrex $6,000 for safety violations after an explosion at its facility in Charles City.
Contracting giant Patheon hopes that new intermediate scale, QbD compatible API manufacturing capabilities will broaden its offering to the drug industry and enable it to cement its market position.
